With zero revenue across ten consecutive quarters leaving all margins undefined, Galectin's operating loss narrowed 68% from $12.4M in 2024Q4 to $4.0M in 2026Q2 purely through an 81% R&D cut, though the 2026Q2 net loss of $9.1M exceeded the operating loss by $5.1M amid record $963K in stock-based compensation.
Galectin Therapeutics Inc. (GALT) annual income statement — 26-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 |
|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1K | 7K | 7K | 0 | 0 | 0 | 0 | 0 | 0 | 49K | 64K | 67K | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1K | -7K | -7K | 0 | 0 | 0 | 0 | 0 | 0 | -5.33M | -6.46M | -7.05M | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | 100% | 85.71% | 0% | - | - | - | - | - | - | 100% | 17.49% | 8.41% | - | - | - | - | - | - | - |
| Operating Expenses | 14.79M | 20.09M | 42.43M | 38.07M | 38.35M | 30.18M | 23.44M | 13.44M | 13.6M | 16.25M | 21.48M | 20.08M | 15.43M | 12.1M | 9.9M | 10.41M | 4.88M | 6.09M | 5.33M | 6.46M | 7.05M | 6.66M | 7.3M | 4.94M | 3.29M | 2.18M | 170K |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 6.93M | 5.79M | 5.86M | 5.94M | 6.62M | 6.36M | 5.47M | 5.97M | 7.13M | 4.53M | 6.16M | 6.96M | 7M | 6.42M | 5.37M | 6.86M | 3.82M | 4.98M | 3.55M | 4.4M | 4.03M | 3.62M | 4.26M | 2.99M | 1.8M | 1.29M | 70K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 7.86M | 14.29M | 36.57M | 32.13M | 31.74M | 23.82M | 17.98M | 7.47M | 6.47M | 11.72M | 15.32M | 13.11M | 8.43M | 5.69M | 4.53M | 3.55M | 1.07M | 1.11M | 1.77M | 2.05M | 3.02M | 3.04M | 3.04M | 1.95M | 1.48M | 893.46K | 100K |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -11.42M | -20.09M | -42.43M | -38.07M | -38.35M | -30.18M | -23.44M | -13.44M | -13.6M | -16.25M | -21.48M | -20.08M | -15.43M | -12.1M | -9.9M | -10.41M | -4.88M | -6.09M | -5.33M | -6.46M | -7.05M | -6.66M | -7.3M | -4.94M | -3.29M | -2.18M | -170K |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 52.67% | -11.45% | 0.73% | -27.08% | -28.73% | -74.46% | 1.21% | 16.28% | 24.37% | -6.98% | -30.13% | -27.48% | -22.27% | 4.9% | -113.17% | 19.86% | -14.4% | 17.49% | 8.41% | -5.91% | 8.89% | -47.91% | -50.22% | -50.65% | -1183.58% | - |
| EBITDA | -11.37M | -20.03M | -42.4M | -38.04M | -38.32M | -30.14M | -23.41M | -13.4M | -13.6M | -16.25M | -21.47M | -20.07M | -15.42M | -12.09M | -9.89M | -10.4M | -4.87M | -6.06M | -5.28M | -6.39M | -6.98M | -6.57M | -7.22M | -4.92M | -3.08M | -2.02M | -190K |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 63.67% | 52.75% | -11.45% | 0.73% | -27.15% | -28.75% | -74.65% | 1.46% | 16.28% | 24.35% | -6.98% | -30.17% | -27.52% | -22.26% | 4.9% | -113.51% | 19.57% | -14.76% | 17.43% | 8.45% | -6.19% | 8.99% | -46.87% | -59.88% | -52.08% | -964.54% | - |
| D&A (Non-Cash Add-back) | 57K | 53K | 37K | 33K | 32K | 41K | 36K | 35K | 1K | 1K | 7K | 7K | 10K | 12K | 9K | 9K | 12K | 37K | 49K | 64K | 67K | 81K | 81K | 20.25K | 211.18K | 159.47K | -20K |
| EBIT | -7.45M | -23.51M | -41.51M | -38.27M | -37.74M | -30.04M | -23.38M | -13.21M | -13.56M | -16.23M | -21.48M | -20.03M | -15.79M | -12.09M | -9.68M | -10.91M | -5.63M | -7.46M | -3.15M | -9.08M | -1.34M | -6.86M | -7.18M | -4.87M | -3.26M | -2.18M | -170K |
| Net Interest Income | -5.84M | -7.2M | -5.2M | -2.56M | -981K | -486K | -21K | 144K | -298K | 12K | 0 | 0 | 42K | 0 | 0 | 0 | 0 | 0 | 0 | 452K | 2.13M | 0 | 0 | 65.05K | -391.16K | 0 | 0 |
| Interest Income | 118K | 126K | 338K | 230K | 52K | 3K | 66K | 231K | 38K | 24K | 45K | 52K | 42K | 16K | 24K | 18K | 6K | 3K | 30K | 102K | 281K | 111K | 124K | 68.92K | 24.26K | 24.92K | 0 |
| Interest Expense | 5.14M | 7.33M | 5.54M | 2.79M | 1.03M | 489K | 87K | 87K | 336K | 12K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 350K | 1.85M | 0 | 0 | 3.88K | 415.42K | 0 | 0 |
| Other Income/Expense | -8.23M | -10.75M | -4.61M | -2.99M | -424K | -348K | -21K | 144K | -298K | 12K | 45K | 52K | -358K | 16K | 224K | -506K | -746K | -1.37M | 2.17M | -2.98M | 3.85M | 111K | 124K | 65.05K | -391.16K | 0 | -20K |
| Pretax Income | -23.19M | -30.84M | -47.05M | -41.07M | -38.78M | -30.53M | -23.46M | -13.29M | -13.9M | -16.23M | -21.44M | -20.03M | -15.79M | -12.09M | -9.68M | -10.91M | -5.63M | -7.46M | -3.15M | -9.43M | -3.19M | -6.54M | -7.18M | -4.87M | -3.68M | -2.18M | -190K |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.79M | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -81.95% | 0% |
| Net Income | -23.19M | -30.84M | -47.05M | -41.07M | -38.78M | -30.53M | -23.46M | -13.29M | -13.9M | -16.23M | -21.44M | -20.03M | -15.79M | -12.09M | -9.68M | -10.91M | -5.63M | -7.46M | -3.15M | -9.43M | -3.19M | -6.54M | -7.18M | -4.87M | -3.68M | -3.97M | -190K |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 37.83% | 34.46% | -14.56% | -5.91% | -27.02% | -30.1% | -76.51% | 4.36% | 14.38% | 24.26% | -7.04% | -26.85% | -30.61% | -24.94% | 11.36% | -93.91% | 24.56% | -136.81% | 66.6% | -195.43% | 51.21% | 8.86% | -47.34% | -32.48% | 7.35% | -1989.62% | - |
| Net Income (Continuing) | -23.19M | -30.84M | -47.05M | -41.07M | -38.78M | -30.53M | -23.46M | -13.29M | -13.9M | -16.23M | -21.44M | -20.03M | -15.79M | -12.09M | -9.68M | -10.91M | -5.63M | -7.46M | -3.15M | -9.43M | -3.19M | -6.54M | -7.18M | -4.87M | -3.68M | -3.97M | -190K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.26 | -0.48 | -0.76 | -0.74 | -0.65 | -0.52 | -0.41 | -0.39 | -0.35 | -0.46 | -0.73 | -0.83 | -0.72 | -0.72 | -0.64 | -0.91 | -0.60 | -0.93 | -0.40 | -1.45 | -0.67 | -1.44 | -1.67 | -1.37 | -1.35 | -1.75 | -0.09 |
| EPS Growth % | 42.88% | 36.84% | -2.7% | -13.85% | -25% | -26.83% | -5.13% | -11.43% | 23.91% | 36.99% | 12.05% | -15.28% | 0% | -12.5% | 29.67% | -51.67% | 35.48% | -132.5% | 72.41% | -116.42% | 53.47% | 13.77% | -21.9% | -1.48% | 22.86% | -1798.05% | - |
| EPS (Basic) | - | -0.48 | -0.76 | -0.74 | -0.65 | -0.52 | -0.41 | -0.39 | -0.35 | -0.46 | -0.73 | -0.83 | -0.72 | -0.72 | -0.64 | -0.91 | -0.60 | -0.93 | -0.40 | -1.45 | -0.67 | -1.44 | -1.67 | -1.37 | -1.35 | -1.75 | -0.09 |
| Diluted Shares Outstanding | 89.62M | 63.9M | 62.31M | 60.16M | 59.39M | 58.53M | 57.03M | 52.24M | 39.41M | 35.52M | 29.22M | 24.12M | 21.85M | 16.87M | 15.13M | 11.99M | 9.38M | 8.05M | 7.8M | 6.5M | 4.75M | 4.55M | 4.29M | 3.56M | 2.73M | 2.27M | 2.06M |
| Basic Shares Outstanding | 89.62M | 63.9M | 62.31M | 60.16M | 59.39M | 58.53M | 57.03M | 52.24M | 39.41M | 35.52M | 29.22M | 24.12M | 21.85M | 16.87M | 15.13M | 11.99M | 9.38M | 8.05M | 7.8M | 6.5M | 4.75M | 4.55M | 4.29M | 3.56M | 2.73M | 2.27M | 2.06M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying GALT stock.
For fiscal year 2025, Galectin Therapeutics Inc. (GALT) reported total revenue of $0.0M.
Galectin Therapeutics Inc. (GALT) reported a net loss of $30.8M for the fiscal year ending 2025.
Key Metrics
Top Statement Risk
Zero Revenue Against Persistent Burn
Metrics are mathematically derived from official filings.
No Revenue Across Ten Quarters
Galectin reported no revenue, zero cost of goods, and nil gross profit across all ten quarters through 2026Q2, per its quarterly income statements, leaving every margin metric undefined and making pipeline optionality, not operating performance, the sole driver of equity value.
The flat zero top line means conventional growth, gross margin, and operating margin comparisons against royalty-earning peers such as HALO (78.1% gross margin) or product-generating AKBA are analytically meaningless, so valuation must rest on discounting future program outcomes rather than current earnings power. Because revenue is absent rather than declining, the growth signal is best read as structurally stable, but it implies that any multiple applied to GALT is effectively a bet on commercial or partnership timing the income statement cannot yet confirm.
R&D Compression Reshapes Cost Base
According to reported operating expenses, R&D spending fell from $11.1M in 2024Q4 to $2.1M in 2026Q2, an 81% reduction, while SG&A drifted up to $1.8M, rebalancing the cost mix from roughly 90% R&D-driven to nearly even with overhead.
R&D's share of total operating expense appears to have dropped from about 90% at the 2024Q4 peak to roughly 54% in 2026Q2, which suggests either program prioritization or trial-stage transitions, though the supplied data does not break out spend by candidate and warrants further investigation. Meanwhile SG&A holding in a tight $1.3M–$1.8M band across ten quarters indicates disciplined fixed overhead, meaning management has protected administrative capacity even while cutting the scientific budget aggressively.
Losses Narrow Through Cost Contraction
Based on reported operating results, quarterly operating losses shrank from $12.4M in 2024Q4 to $4.0M in 2026Q2, a 68% improvement achieved entirely through cost contraction rather than revenue contribution, since the top line remains nil throughout the period.
With gross profit at zero, conventional operating leverage is undefined; what the series shows instead is expense-driven loss compression, with average quarterly operating losses moving from roughly $10.6M in 2024 to about $5.0M in 2025 and near $4.1M in early 2026. The implication is a lower quarterly burn floor, but it also means there is no revenue base over which to spread overhead, so any future top line would arrive against a cost structure already sized for a pre-commercial organization.
Below-Line Items Cloud Net Loss
As reported in Galectin's quarterly results, the 2026Q2 net loss of $9.1M exceeded the $4.0M operating loss by $5.1M, while stock-based compensation rose to $963K, its highest level in the ten-quarter series, suggesting non-operating volatility masks the operating trend.
The gap between operating and net results is not confined to 2026Q2, as 2025Q3 also showed an $8.2M net loss against a $4.2M operating loss, so below-the-line items appear recurrent rather than one-off, though their composition is not detailed in the supplied data and warrants further investigation. Elevated SBC alongside declining R&D also suggests a shift in how the company is compensating stakeholders as trial spending tapers, which investors should monitor for dilution pressure even as headline operating losses improve.
2024Q4 Marked R&D Spending Peak
The 2024Q4 period stands out as the operational inflection point, with R&D reaching $11.1M and the operating loss hitting $12.4M, after which quarterly R&D stayed at or below $6.5M from 2025Q1 onward, per Galectin's quarterly income statements, thereby materially resetting the burn profile.
The step-down is persistent rather than seasonal: net losses averaged roughly $11.8M per quarter in 2024, improved to about $7.7M in 2025, and held near $7.1M in the first half of 2026, which appears consistent with the completion or scaling back of a major study phase. The lasting impact is a structurally lower expense base, but it also raises the question of whether pipeline breadth has narrowed alongside the budget, a distinction the income statement alone cannot resolve.
Cost Cuts Cannot Replace Pipeline
The bear case centers on GALT reporting zero revenue for ten consecutive quarters while the operating loss still runs near $4.0M per quarter, meaning continued expense reduction alone cannot close the gap absent a commercial or partnership inflection investors cannot yet underwrite.
A short-seller would likely focus on the $5.1M divergence between operating and net loss in 2026Q2 alongside rising SBC of $963K, arguing that headline burn improvement is flattered by cost cuts while equity compensation and non-operating charges quietly erode earnings quality. The counterweight is that SG&A discipline has been consistent and operating losses are genuinely narrowing, yet with R&D already down 81% from peak, further savings may have diminishing room, so the downside scenario is one where the floor in losses is reached before any revenue arrives.